EUVIMEDEUVIMED entdecken
Crossref

A Shot at Urinary Tract Infection Prevention: Lessons from Global Use of UTI Vaccines

Tarlan Torabi

Galter Health Sciences Library, Northwestern University · 21.04.2026

DOI: 10.18131/5ca8q-wkp15 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Galter Health Sciences Library, Northwestern University, erschienen am 21.04.2026. Verfasst von Tarlan Torabi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urinary Tract Infections (UTIs) are the second most common infectious disease globally. In the United States, UTIs continue to pose a particular threat to female adult populations, with a lifetime incidence of 50-60% in adult women. The current primary treatment regimen for UTIs is antibiotic therapy; however, the growing prevalence of antimicrobial resistance, especially among Escherichia coli (E. coli) strains, is contributing to therapeutic failure and related complications. Considering this growing challenge, the exploration of alternative therapeutic strategies for UTIs, especially vaccine-based interventions, has become increasingly important.

Objectives

To evaluate how UTI vaccine-based immunoprophylaxis, compared with standard non-vaccine prevention strategies, affects UTI recurrence rates, antibiotic use, and healthcare utilization based on international data, and to assess the implications for U.S. clinical practice.

Design

Systematic literature review Methods: The National Library of Medicine PubMed database was searched using terms including “UTI vaccine” and “recurrent UTI treatment.” A variety of exclusion and inclusion criteria were incorporated and ultimately 3 studies were selected. These studies were analyzed for outcomes and validity assessments were conducted.

Results

Study #1: up to 9.4-fold increase in antibody titers against all targeted serotypes, significant reduction in UTIs caused by E. coli of any serotype (0.207 vs 0.463 episodes, p = 0.002) Study #2: significant reduction in UTIs (3.14 vs 0.84 episodes, p < 0.001) Study #3: significant reduction in UTIs (3.14 vs 1.53 episodes, p < 0.05)

Conclusion

The current international evidence suggests that UTI vaccine-based immunoprophylaxis demonstrates promising reductions in infection recurrence and reliance on antibiotics. These findings highlight the potential role of vaccine strategies in addressing recurrent UTIs while helping to mitigate antimicrobial resistance. Further research and large-scale studies are needed to determine the applicability of these interventions within U.S. clinical practice.

Schlagwörter

urinary tract infectionimmunoprophylaxisrecurrent urinary tract infectionEscherichia coliserotype-specific antibodiesantimicrobial resistanceantibiotic usehealth care utilizationwomen's health

Zitieren

APA

Torabi, T. (2026). A Shot at Urinary Tract Infection Prevention: Lessons from Global Use of UTI Vaccines. Galter Health Sciences Library, Northwestern University. https://doi.org/10.18131/5ca8q-wkp15

Vancouver

Torabi T. A Shot at Urinary Tract Infection Prevention: Lessons from Global Use of UTI Vaccines. Galter Health Sciences Library, Northwestern University. 2026. doi:10.18131/5ca8q-wkp15

BibTeX
@article{Torabi2026,
  author = {Torabi, Tarlan},
  title = {A Shot at Urinary Tract Infection Prevention: Lessons from Global Use of UTI Vaccines},
  journal = {Galter Health Sciences Library, Northwestern University},
  year = {2026},
  doi = {10.18131/5ca8q-wkp15}
}
Kostenlos starten →